Mostrar el registro sencillo del ítem
Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial
hal.structure.identifier | Institut méditerranéen de biodiversité et d'écologie marine et continentale [IMBE] | |
dc.contributor.author | LORET, Erwann | |
hal.structure.identifier | Hôpital de la Conception [CHU - APHM] [LA CONCEPTION] | |
dc.contributor.author | DARQUE, Albert | |
hal.structure.identifier | Hôpital de la Timone [CHU - APHM] [TIMONE] | |
dc.contributor.author | JOUVE, Elisabeth | |
dc.contributor.author | LORET, Elvenn | |
hal.structure.identifier | Aix-Marseille Université - Faculté de pharmacie [AMU PHARM] | |
dc.contributor.author | NICOLINO-BRUNET, Corinne | |
hal.structure.identifier | Centre d'Investigation Clinique [Hôpital de la Conception - APHM] [CIC] | |
dc.contributor.author | MORANGE, Sophie | |
hal.structure.identifier | Assistance Publique - Hôpitaux de Marseille [APHM] | |
dc.contributor.author | CASTANIER, Elisabeth | |
hal.structure.identifier | Assistance Publique - Hôpitaux de Marseille [APHM] | |
dc.contributor.author | CASANOVA, Josiane | |
hal.structure.identifier | Institut de Biologie du Développement de Marseille [IBDM] | |
dc.contributor.author | CALOUSTIAN, Christine | |
hal.structure.identifier | Assistance Publique - Hôpitaux de Marseille [APHM] | |
dc.contributor.author | BORNET, Charleric | |
hal.structure.identifier | Hôpital de la Conception [CHU - APHM] [LA CONCEPTION] | |
dc.contributor.author | COUSSIROU, Julie | |
hal.structure.identifier | Hôpital de la Conception [CHU - APHM] [LA CONCEPTION] | |
dc.contributor.author | BOUSSETTA, Jihen | |
hal.structure.identifier | Institut de Mathématiques de Bordeaux [IMB] | |
dc.contributor.author | COUALLIER, Vincent | |
hal.structure.identifier | Clinical Investigation Centre (CIC-UPCET) and Department of Clinical Pharmacology, | |
dc.contributor.author | BLIN, Olivier | |
hal.structure.identifier | Chirurgie urologique et transplantation rénale [Hôpital de la Conception - APHM] | |
dc.contributor.author | DUSSOL, Bertrand | |
hal.structure.identifier | Service des Maladies Infectieuses et Tropicales [Hôpital de la Conception] [SMIT] | |
dc.contributor.author | RAVAUX, Isabelle | |
dc.date.accessioned | 2024-04-04T03:01:39Z | |
dc.date.available | 2024-04-04T03:01:39Z | |
dc.date.issued | 2016-12 | |
dc.identifier.issn | 1742-4690 | |
dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/192916 | |
dc.description.abstractEn | Background: A Tat Oyi vaccine preparation was administered with informed consent to 48 long-term HIV-1 infected volunteers whose viral loads had been suppressed by antiretroviral therapy (cART). These volunteers were rand-omized in double-blind method into four groups (n = 12) that were injected intradermally with 0, 11, 33, or 99 µg of synthetic Tat Oyi proteins in buffer without adjuvant at times designated by month 0 (M0), M1 and M2, respectively. The volunteers then underwent a structured treatment interruption between M5 and M7. Results: The primary outcomes of this phase I/IIa clinical trial were the safety and lowering the extent of HIV RNA rebound after cART interruption. Only one undesirable event possibly due to vaccination was observed. The 33 µg dose was most effective at lowering the extent of HIV RNA and DNA rebound (Mann and Whitney test, p = 0.07 and p = 0.001). Immune responses against Tat were increased at M5 and this correlated with a low HIV RNA rebound at M6 (p = 0.01). Conclusion: This study suggests in vivo that extracellular Tat activates and protects HIV infected cells. The Tat Oyi vaccine in association with cART may provide an efficient means of controlling the HIV-infected cell reservoir. | |
dc.language.iso | en | |
dc.publisher | BioMed Central | |
dc.subject.en | ART interruption | |
dc.subject.en | Vaccine | |
dc.subject.en | Clinical trial | |
dc.subject.en | Tat | |
dc.subject.en | HIV | |
dc.title.en | Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial | |
dc.type | Article de revue | |
dc.identifier.doi | 10.1186/s12977-016-0251-3 | |
dc.subject.hal | Sciences du Vivant [q-bio] | |
dc.subject.hal | Sciences du Vivant [q-bio]/Immunologie | |
dc.subject.hal | Sciences du Vivant [q-bio]/Immunologie/Vaccinologie | |
bordeaux.journal | Retrovirology | |
bordeaux.volume | 13 | |
bordeaux.hal.laboratories | Institut de Mathématiques de Bordeaux (IMB) - UMR 5251 | * |
bordeaux.issue | 1 | |
bordeaux.institution | Université de Bordeaux | |
bordeaux.institution | Bordeaux INP | |
bordeaux.institution | CNRS | |
bordeaux.peerReviewed | oui | |
hal.identifier | hal-02077548 | |
hal.version | 1 | |
hal.popular | non | |
hal.audience | Internationale | |
hal.origin.link | https://hal.archives-ouvertes.fr//hal-02077548v1 | |
bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Retrovirology&rft.date=2016-12&rft.volume=13&rft.issue=1&rft.eissn=1742-4690&rft.issn=1742-4690&rft.au=LORET,%20Erwann&DARQUE,%20Albert&JOUVE,%20Elisabeth&LORET,%20Elvenn&NICOLINO-BRUNET,%20Corinne&rft.genre=article |
Archivos en el ítem
Archivos | Tamaño | Formato | Ver |
---|---|---|---|
No hay archivos asociados a este ítem. |